GlobeNewswire

Abiomed Announces Q1 FY 2018 Revenue of $132.5 Million, Up 29% Over Prior Year

Del

Company announces Japanese reimbursement for Impella® heart pumps and raises lower end of FY 2018 revenue guidance

DANVERS, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2018 revenue of $132.5 million, an increase of 29% compared to revenue of $103.0 million for the same period of fiscal 2017. First quarter fiscal 2018 GAAP net income was $37.4 million or $0.82 per diluted share, compared to GAAP net income of $12.9 million or $0.29 per diluted share for the prior year period.  

Financial and operating highlights during the first quarter of fiscal 2018 include:

  • Fiscal first quarter worldwide revenue from Impella® heart pumps totaled $127.2 million, an increase of 30% compared to revenue of $97.8 million during the same period of the prior fiscal year.  U.S. revenue from Impella heart pumps grew 28% to $114.7 million and U.S. Impella patient usage grew 27%.  
     
  • Outside the U.S., revenue from Impella heart pumps totaled $12.5 million and was up 53%, predominately from Germany, which grew 62% in revenue from the prior fiscal year.
     
  • The installed base for Impella 2.5® heart pumps in the U.S. grew by an additional 16 hospitals, which made initial purchases of Impella heart pumps, bringing the installed customer base to 1,154 sites. The installed customer base for Impella CP® heart pumps grew by 46 new U.S. hospitals, bringing the total number of Impella CP sites to 1,062. The installed customer base for Impella 5.0® heart pumps grew by 19 new U.S. hospitals, bringing the total number of Impella 5.0 sites to 472.
     
  • An additional 15 sites made initial purchases of the Impella RP® heart pumps during the quarter, bringing the total number to 142 sites.
     
  • Gross margin for fiscal first quarter 2018 was 83.5% compared to 85.4% in the first quarter of fiscal 2017. 
     
  • Operating income for the first quarter of fiscal 2018 was $33.1 million, or 25.0% operating margin, compared to $21.2 million, or 20.6% operating margin in the prior year period. 
     
  • First quarter fiscal 2018 GAAP net income was $37.4 million or $0.82 per diluted share, which benefited from the adoption of a new accounting standard that required $16.8 million, or $0.37 per diluted share, of excess tax benefits related to employee share-based compensation awards be recorded as a reduction of income tax expense. This compared to GAAP net income of $12.9 million or $0.29 per diluted share for the prior year period, before new accounting standards.
     
  • The Company generated $12.0 million in cash, cash equivalents and marketable securities, totaling $289.1 million as of June 30, 2017, compared to $277.1 million at March 31, 2017. The Company incurs annual cash outlays in the first quarter and currently has no debt.
     
  • The Company has recently received approval from the Japanese Ministry Health Labour and Welfare (MHLW) for reimbursement on Impella 2.5 and 5.0 Impella heart pumps and 10 physician societies have completed the hospital guidance document. At recent average exchange rates, reimbursement in Japan is estimated to be $24,000, equivalent to our Impella sales price in the U.S., and commences this September. We expect our first Japanese patient in September and are reiterating our controlled Impella launch at 10 hospitals by end of this fiscal year in March.
     
  • On June 30, a new study of Abiomed's Impella 2.5 heart pump demonstrated potential survival benefit with pre-PCI insertion in heart attacks with the left main coronary artery.

"We have been notified by MHLW of Japanese reimbursement for Impella beginning in September allowing our introduction into the world's second largest medical device market," said Michael R. Minogue, Chairman, President and Chief Executive Officer, Abiomed. "Our continued execution validates Abiomed as one of the fastest growing medical technology companies with increasing GAAP profitability and no debt. I am proud of our team's ability to consistently achieve our strategic initiatives and execute on our tactical plan as Abiomed builds the Field of Heart Recovery."

FISCAL YEAR 2018 OUTLOOK
The Company is increasing the lower end of its fiscal year 2018 revenue guidance by $5 million to a new range of $560 million to $575 million, an increase in revenue of 26% to 29% from the prior year. This compares to the prior forecast of $555 million to $575 million. The Company is maintaining its fiscal year guidance for GAAP operating margin in the range of 22% to 24%.

CONFERENCE CALL
The Company will host a conference call to discuss the results on Thursday, July 27, 2017, at 8:00 a.m. EDT. Michael R. Minogue, Chairman, President and Chief Executive Officer; Michael Tomsicek, Vice President and Chief Financial Officer, will host the conference call.

To listen to the call live, please tune into the webcast via http://investor.abiomed.com or dial (855) 212-2361; the international number is (678) 809-1538.  A replay of this conference call will be available beginning at 11 a.m. EDT July 27, 2017 through 11 a.m. EDT on July 30, 2017. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 51159965.

ABOUT ABIOMED 
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.  Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com

FORWARD-LOOKING STATEMENTS 
This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

 
Abiomed, Inc. and Subsidiaries
Consolidated Balance Sheets
(Unaudited)
(in thousands, except share data)
         
    June 30, 2017   March 31, 2017
         
ASSETS        
Current assets:        
Cash and cash equivalents   $   43,970     $   39,040  
Short-term marketable securities     207,441         190,908  
Accounts receivable, net        53,557         54,055  
Inventories        36,926         34,931  
Prepaid expenses and other current assets       9,021         8,024  
Total current assets     350,915         326,958  
Long-term marketable securities       37,669         47,143  
Property and equipment, net       92,804         87,777  
Goodwill       33,199         31,045  
In-process research and development       15,487         14,482  
Long-term deferred tax assets, net     113,457         34,723  
Other assets       8,686         8,286  
Total assets   $ 652,217     $   550,414  
LIABILITIES AND STOCKHOLDERS' EQUITY        
Current liabilities:        
Accounts payable   $   12,784     $   20,620  
Accrued expenses       35,695         37,703  
Deferred revenue       9,697         10,495  
Current portion of capital lease obligation       829         799  
Total current liabilities       59,005         69,617  
Other long-term liabilities       588         3,251  
Contingent consideration       9,418         9,153  
Long-term deferred tax liabilities       837         783  
Capital lease obligation, net of current portion       15,325         15,539  
Total liabilities       85,173         98,343  
Commitments and contingencies        
Stockholders' equity:        
Class B Preferred Stock, $.01 par value       -         -  
Authorized - 1,000,000 shares; Issued and outstanding - none        
Common stock, $.01 par value       441         437  
Authorized - 100,000,000 shares; Issued - 45,791,680 shares at June 30, 2017 and 45,249,281 shares at March 31, 2017         
Outstanding - 44,080,941 shares at June 30, 2017 and 43,673,286 shares at March 31, 2017        
Additional paid in capital     580,017         565,962  
Retained earnings (accumulated deficit)       65,661         (46,959 )
Treasury stock at cost - 1,710,739 shares at June 30, 2017  and 1,575,995 shares at March 31, 2017      (64,567 )       (46,763 )
Accumulated other comprehensive loss     (14,508 )       (20,606 )
Total stockholders' equity     567,044         452,071  
Total liabilities and stockholders' equity   $ 652,217     $   550,414  
         

Abiomed, Inc. and Subsidiaries  
Consolidated Statements of Operations  
(Unaudited)  
(in thousands, except per share data)  
             
             
  Three Months Ended 
June 30,
 
  2017     2016    
Revenue:            
Product revenue $   132,431     $   102,989    
Funded research and development     37         6    
      132,468         102,995    
Costs and expenses:            
Cost of product revenue      21,862         15,070    
Research and development      16,931         15,660    
Selling, general and administrative      60,597         51,032    
      99,390         81,762    
Income from operations     33,078         21,233    
Other income:            
Investment income, net     635         269    
Other income (expense), net     79         (77 )  
      714         192    
Income before income taxes     33,792         21,425    
Income tax (benefit) provision (1)     (3,582 )       8,515    
Net income $   37,374     $   12,910    
             
Basic net income per share $   0.85     $   0.30    
Basic weighted average shares outstanding     43,895         42,811    
             
Diluted net income per share (2) $   0.82     $   0.29    
Diluted weighted average shares outstanding     45,608         45,178    
             
             
(1) Income tax provision includes the effect of the following item:            
Excess tax benefits related to stock-based compensation awards * $   16,842     $   -    
             
(2) Diluted net income per share includes the effect of the following item:            
Excess tax benefits related to stock-based compensation awards * $   0.37     $   -    
             
* In the first quarter of fiscal 2018, the Company adopted Accounting Standards Update No. 2016-09, Improvements to Employee Share-Based Payment Accounting, which requires that all excess tax benefits and tax deficiencies related share-based compensation arrangements be recognized as income tax benefit or expense, instead of in stockholders' equity as previous guidance required.  
             

For further information please contact: 

Ingrid Goldberg Ward
Director, Investor Relations
978-646-1590
ir@abiomed.com

Adrienne Smith
Senior Director, Public Relations and Corporate Communications
978-646-1553
adsmith@abiomed.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Abiomed via Globenewswire

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Altus Group Report Reveals Rapid Acceleration of PropTech Adoption and Rise of Disintermediation as Major Trends Impacting the Commercial Real Estate Industry in 201922.1.2019 15:00Pressemelding

Automation, use of AI and disintermediating business models having major impact on CRE industry; growing number of CRE firms are directly investing in PropTech companies TORONTO, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Altus Group Limited (“Altus Group”) (TSX: AIF), a leading provider of software, data solutions and independent advisory services to the global commercial real estate (“CRE”) industry, today released the latest Altus Group CRE Innovation Report. The report provides an outlook on technology trends impacting the global CRE industry and highlights the significant acceleration in adoption of property technology (“PropTech”), the effect of disintermediating technologies, as well as a growing trend of CRE firms investing directly in PropTech companies and startups themselves. According to the report, which is based on a global survey of 400 CRE executives at firms with assets under management (“AUM”) of at least US $250 million representing a total AUM of over US $2 trillion, driving

K2 Acquires Distributor K2NE, Strengthening Its Digital Process Automation Capabilities Across Europe22.1.2019 15:00Pressemelding

Acquisition expands the digital process automation company’s presence into new markets Bellevue, Wash., Jan. 22, 2019 (GLOBE NEWSWIRE) -- SourceCode Technology Holdings, Inc. (“K2”), the leader in low-code digital process automation, today announced the acquisition of one of its distributors, K2NE. With this acquisition, K2 establishes a direct presence in mainland Europe, increasing the direct customer footprint to 14 European countries, further investing and committing to growth across the continent. K2 customers will now see increased opportunities and offerings centered around strengthening their digital transformation. K2NE has a demonstrated history of strong business growth and success gaining market shares in Spain, Switzerland and Germany. “We are thrilled to welcome the K2NE team to the K2 family,” said Evan Ellis, K2 CEO. “As two organizations built around customer-first approaches to digital process automation, we can together leverage our common vision, expand our geograph

ATTO Technology is Now Certified DataCore Ready™ and will Showcase at the DataCore Partner Conference in Frankfurt, Germany22.1.2019 14:47Pressemelding

AMHERST, N.Y., Jan. 22, 2019 (GLOBE NEWSWIRE) -- ATTO Technology, Inc., a global leader of storage, network connectivity and infrastructure solutions for data-intensive computing environments for over 30 years, is proud to announce ATTO Celerity™ Gen 6 32Gb and 16Gb Fibre Channel host bus adapters (HBAs) are certified DataCore Ready™. In addition, as a member of the DataCore Ready Partner Program, ATTO will highlight its certified connectivity options for software-defined storage and data management solutions at the DataCore Partner Conference January 22-23 in Frankfurt, Germany. “We are excited to certify the ATTO Celerity HBAs as DataCore Ready as they will help IT departments achieve the flexibility and freedom that software-defined storage solutions offer, while providing the network performance and reliability that mission-critical applications need,” said Gerardo Dada, CMO of DataCore Software. “We look forward to seeing the products in action at our annual partner conference.” A

PEX Network and iGrafx Release Research Report22.1.2019 14:00Pressemelding

Primary Research and Analysis Describes Challenges and Opportunities for Digital Transformation Professionals Orlando, FL, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Today at the OPEX Week: Business Transformation World Summit, PEX Network and iGrafx announced that they completed an extensive primary research project designed to answer the question: “Disrupted or Disruptor – Which Side Are You On?” More than 150 business leaders and digital business transformation experts from 36 industries and 42 countries participated in the survey and provided detailed insights on a range of pressing topics. PEX Networks Editor, Ian Hawkins managed the project and orchestrated analysis and insights from across his organization. “I was frankly surprised and delighted with the breadth and depth of feedback we received from members of the PEX Network community,” said Hawkins. “We now have unprecedented perspective gleaned from respondents on topics like: how to select the right processes to automate, how to mea

CEO confidence in growth dips dramatically21.1.2019 18:45Pressemelding

Uncertainty in global economic growth in almost all countries, caution prevails US remains key target market for growth with China narrowing the gap, both see a decline from 2018 Trade conflicts, policy uncertainty, geopolitical issues and skills gap impacting strength of global economy and growth DAVOS, Switzerland, Jan. 21, 2019 (GLOBE NEWSWIRE) -- What a difference a year makes. Nearly 30% of business leaders believe that global economic growth will decline in the next 12 months, approximately six times the level of 5% last year – a record jump in pessimism. This is one of the key findings of PwC’s 22nd annual survey of 1,300 plus CEOs around the world, launched today at the World Economic Forum Annual Meeting in Davos. This is in vivid contrast to last year’s record jump, 29% to 57%, in optimism about global economic growth prospects. Although, all is not doom and gloom: 42% still see an improved economic outlook, though this is down significantly from a high of 57% in 2018. Overal

Komet announces initial Mineral Resource Estimate for the Kabaya Prospect, (Dabia Sud property, Mali)21.1.2019 15:10Pressemelding

QUEBEC CITY, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Komet Resources inc. (TSX-V: KMT) (“Komet” or the “Company”) is pleased to report an initial mineral resource estimate for the Kabaya gold prospect drill prospect, located in the southern part of its Dabia Sud exploration permit (“the Property”) in Western Mali, West Africa. Highlights of the Resource Estimate include : An Indicated Resource of 3.17 million tonnes (Mt) grading 1.03 g/t for 105,000 contained gold ounces and an Inferred Resource of 0.96 Mt grading 1.14 g/t for 35,000 contained gold ounces at a cut-off grade of 0.40 g/t Au (table 1). The pit constrained resource is based on optimized pit shells using a gold price of 1350 US$ and a presumed heap leach gold recovery of saprolite ore. Gold mineralization at Kabaya remains open at depth in bedrock and laterally to the south-west and north-west. Komet intends to continue the resource definition drilling program in order to further develop the resource laterally in saprolite and at